Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

(Bloomberg) -- Bayer AG’s kidney drug Kerendia helped patients avoid complications from a common form of heart failure in a ...

The analysts named Mesoblast’s stem cell therapy Revascor and Bayer’s Kerendia as other promising prospects. All four companies have late-phase data in heart failure. Novo was closing in on ...